These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 31742831

  • 1. Clinical application of Web Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Patterns of blood sampling and patient characteristics among clinician users.
    McEneny-King A, Yeung CH, Edginton AN, Iorio A, Croteau SE.
    Haemophilia; 2020 Jan; 26(1):56-63. PubMed ID: 31742831
    [Abstract] [Full Text] [Related]

  • 2. A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa.
    Arvanitakis A, Berntorp E, Astermark J.
    Haemophilia; 2021 May; 27(3):417-424. PubMed ID: 33751755
    [Abstract] [Full Text] [Related]

  • 3. A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients.
    Yu JK, Iorio A, Edginton AN.
    Thromb Res; 2020 Dec; 196():550-558. PubMed ID: 33157394
    [Abstract] [Full Text] [Related]

  • 4. Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo project.
    Hajducek DM, Chelle P, Hermans C, Iorio A, McEneny-King A, Yu J, Edginton A.
    Haemophilia; 2020 May; 26(3):384-400. PubMed ID: 32281726
    [Abstract] [Full Text] [Related]

  • 5. Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup.
    Chelle P, Yeung CHT, Croteau SE, Lissick J, Balasa V, Ashburner C, Park YS, Bonanad S, Megías-Vericat JE, Nagao A, Wynn T, Corrales-Medina F, Tran H, Sharathkumar A, Chitlur M, Sarmiento S, Edginton A, Iorio A.
    Clin Pharmacokinet; 2020 Feb; 59(2):245-256. PubMed ID: 31435896
    [Abstract] [Full Text] [Related]

  • 6. Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo).
    McEneny-King A, Foster G, Iorio A, Edginton AN.
    JMIR Res Protoc; 2016 Dec 07; 5(4):e232. PubMed ID: 27927609
    [Abstract] [Full Text] [Related]

  • 7. Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Study Protocol.
    Iorio A, Keepanasseril A, Foster G, Navarro-Ruan T, McEneny-King A, Edginton AN, Thabane L, WAPPS-Hemo co-investigator network.
    JMIR Res Protoc; 2016 Dec 15; 5(4):e239. PubMed ID: 27977390
    [Abstract] [Full Text] [Related]

  • 8. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics.
    Nummi V, Lehtinen AE, Iorio A, Szanto T, Lassila R.
    Haemophilia; 2022 Nov 15; 28(6):e237-e244. PubMed ID: 35939628
    [Abstract] [Full Text] [Related]

  • 9. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
    Carcao MD, Chelle P, Clarke E, Kim L, Tiseo L, Morfini M, Hossain T, Rand ML, Brown C, Edginton AN, Lillicrap D, Iorio A, Blanchette VS.
    J Thromb Haemost; 2019 Jul 15; 17(7):1085-1096. PubMed ID: 31038793
    [Abstract] [Full Text] [Related]

  • 10. Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII.
    Preijers T, van Moort I, Fijnvandraat K, Leebeek FWG, Cnossen MH, Mathôt RAA, ‘OPTI-CLOT’ Study Group.
    Thromb Haemost; 2018 Mar 15; 118(3):514-525. PubMed ID: 29534249
    [Abstract] [Full Text] [Related]

  • 11. Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi-country severe WAPPS-Hemo haemophilia patients.
    Hajducek DM, Chelle P, Iorio A, Iserman E, Edginton AN.
    Haemophilia; 2024 Jul 15; 30(4):925-932. PubMed ID: 38738967
    [Abstract] [Full Text] [Related]

  • 12. Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients.
    Chelle P, Yeung CHT, Bonanad S, Morales Muñoz JC, Ozelo MC, Megías Vericat JE, Iorio A, Spears J, Mir R, Edginton A.
    J Pharmacokinet Pharmacodyn; 2019 Oct 15; 46(5):427-438. PubMed ID: 31115857
    [Abstract] [Full Text] [Related]

  • 13. External qualification of the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) models for octocog alfa using real patient data.
    Chelle P, Hajducek D, Mahdi M, Young S, Iorio A, Silvertown J, Edginton A.
    Res Pract Thromb Haemost; 2021 Oct 15; 5(7):e12599. PubMed ID: 34761154
    [Abstract] [Full Text] [Related]

  • 14. Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A.
    Astermark J, Olsson A, Chelle P, Täckström K, Walger M, Magnusson M, Iorio A.
    Haemophilia; 2021 Jul 15; 27(4):626-633. PubMed ID: 33966319
    [Abstract] [Full Text] [Related]

  • 15. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
    Croteau SE, Cheng D, Cohen AJ, Holmes CE, Malec LM, Silvey M, Thornburg CD, Wheeler AP, Kouides PA, Raffini LJ, Neufeld EJ.
    Haemophilia; 2019 Jul 15; 25(4):668-675. PubMed ID: 30993845
    [Abstract] [Full Text] [Related]

  • 16. Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database.
    Versloot O, Iserman E, Chelle P, Germini F, Edginton AN, Schutgens REG, Iorio A, Fischer K, Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (IPSG).
    J Thromb Haemost; 2021 Aug 15; 19(8):1896-1906. PubMed ID: 34013558
    [Abstract] [Full Text] [Related]

  • 17. Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing.
    Nagao A, Yeung CHT, Germini F, Suzuki T.
    Thromb Res; 2019 Jan 15; 173():79-84. PubMed ID: 30496937
    [Abstract] [Full Text] [Related]

  • 18. The influence of dead space in blood sampling needle on FVIII level and pharmacokinetic profiles in children with hemophilia.
    Zhen Y, Ai D, Huang K, Li G, Chen Z, Wu R.
    Hematology; 2024 Dec 15; 29(1):2314871. PubMed ID: 38346146
    [Abstract] [Full Text] [Related]

  • 19. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
    Shah A, Coyle T, Lalezari S, Fischer K, Kohlstaedde B, Delesen H, Radke S, Michaels LA.
    Haemophilia; 2018 Sep 15; 24(5):733-740. PubMed ID: 29963724
    [Abstract] [Full Text] [Related]

  • 20. BAY 81-8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study.
    Santoro C, Fuh B, Le PQ, Maes P, Berrueco R, Mingot-Castellano EM, von Mackensen S, Solms A, Wang M.
    Eur J Haematol; 2020 Aug 15; 105(2):164-172. PubMed ID: 32259334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.